Premium Nahrungsergänzungsmittel | artgerecht

Tyrosine Kinase Inhibitors: Action, Uses & Side Effects

Tyrosine kinase inhibitors are targeted cancer drugs that block enzymes controlling cell growth. They are widely used in modern oncology to treat various cancers.

Regular tips about health Regular tips about health

Things worth knowing about "Tyrosine kinase inhibitor"

Tyrosine kinase inhibitors are targeted cancer drugs that block enzymes controlling cell growth. They are widely used in modern oncology to treat various cancers.

What Are Tyrosine Kinase Inhibitors?

Tyrosine kinase inhibitors (TKIs) are a class of medications that selectively block enzymes known as tyrosine kinases. These enzymes act as molecular switches that regulate cell growth, division, and survival. When tyrosine kinases are overactive or mutated, they can drive uncontrolled cell proliferation – a hallmark of cancer. TKIs belong to the category of targeted therapies and represent one of the most important advances in modern oncology.

Mechanism of Action

Tyrosine kinases transfer phosphate groups to proteins, activating signaling pathways that promote cell growth and survival. In many cancers, these enzymes are permanently switched on or overexpressed.

TKIs work by binding to the ATP-binding site of the tyrosine kinase, blocking its activity. This interrupts the downstream signaling cascade, leading to cell growth arrest or programmed cell death (apoptosis) in cancer cells. Unlike conventional chemotherapy, TKIs target specific molecular structures, which generally results in a more favorable side effect profile and greater selectivity for cancer cells.

Indications and Areas of Use

TKIs are used in the treatment of various cancers where specific tyrosine kinases play a driving role:

Chronic myeloid leukemia (CML): Imatinib was the first approved TKI, targeting the BCR-ABL fusion protein.
Non-small cell lung cancer (NSCLC): EGFR inhibitors such as erlotinib, gefitinib, or osimertinib in patients with EGFR mutations.
Breast cancer: HER2-targeted TKIs such as lapatinib or neratinib in HER2-positive breast cancer.
Renal cell carcinoma and other solid tumors: Multikinase inhibitors such as sunitinib or sorafenib.
Gastrointestinal stromal tumors (GIST): Imatinib in patients with KIT mutations.
Thyroid cancer, hepatocellular carcinoma, and other tumor types.

Generations of Tyrosine Kinase Inhibitors

Multiple generations of TKIs have been developed over time, primarily to overcome resistance to earlier compounds:

1st generation: e.g., imatinib, erlotinib, gefitinib
2nd generation: e.g., dasatinib, nilotinib, afatinib – more potent and with a broader spectrum of activity
3rd generation: e.g., osimertinib, ponatinib – specifically designed to overcome resistance mutations such as T790M in EGFR

Administration and Dosage

Most TKIs are administered orally as tablets or capsules, which is a significant advantage over intravenous chemotherapy. Dosage depends on the specific drug, the type of cancer being treated, and the individual condition of the patient. Some TKIs are taken once daily, others twice daily. Treatment is usually continued long-term or indefinitely as long as the therapy remains effective and well-tolerated.

Side Effects

Although TKIs are more targeted than conventional chemotherapy, they can cause a range of side effects:

Common side effects: nausea, diarrhea, skin rash (especially with EGFR inhibitors), fatigue, loss of appetite
Cardiovascular effects: hypertension, QT prolongation, heart failure (with certain TKIs)
Liver toxicity: elevated liver enzymes (hepatotoxicity)
Electrolyte imbalances and changes in blood count
Edema (fluid retention in tissues)
Interstitial lung disease (rare but serious)

Regular monitoring, including blood counts, liver function tests, and cardiac assessments, is essential throughout treatment.

Resistance Development

A well-known challenge of long-term TKI therapy is the development of drug resistance. Cancer cells may acquire mutations in the target enzyme that reduce or abolish drug binding (e.g., the T790M mutation in EGFR). In such cases, next-generation TKIs or alternative treatment strategies are often employed. Molecular diagnostics, such as liquid biopsy, play an increasingly important role in the early detection of resistance mechanisms.

References

Druker BJ et al. - Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. New England Journal of Medicine, 2001.
Arora A, Scholar EM - Role of Tyrosine Kinase Inhibitors in Cancer Therapy. Journal of Pharmacology and Experimental Therapeutics, 2005.
European Medicines Agency (EMA) - Product information for approved tyrosine kinase inhibitors. Available at: www.ema.europa.eu

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.